These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1718379)

  • 21. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with advanced cancer using multiple long-term cultured lymphokine-activated killer (LAK) cell infusions and recombinant human interleukin-2.
    Mittelman A; Savona S; Gafney E; Penichet KO; Lin BY; Levitt D; Ahmed T; Arlin ZA; Baskind P; Needleman D
    J Biol Response Mod; 1989 Oct; 8(5):468-78. PubMed ID: 2795092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic therapy in disseminated melanoma.
    Rümke PH
    Semin Surg Oncol; 1992; 8(6):392-9. PubMed ID: 1279776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous head and neck melanoma: the old and the new.
    Rigual NR; Popat SR; Jayaprakash V; Jaggernauth W; Wong M
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):403-12. PubMed ID: 18366288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep; 5(9):71. PubMed ID: 1835879
    [No Abstract]   [Full Text] [Related]  

  • 26. Malignant melanoma.
    Smyth JF
    Cancer Chemother Biol Response Modif; 1990; 11():531-43. PubMed ID: 2223406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new approach in the treatment of metastatic melanoma: adoptive immunotherapy using lymphokine-activated killer cells and interleukin 2].
    Keilholz U; Welters H; Dummer R; Tilgen W; Hunstein W
    Hautarzt; 1988 Jun; 39(6):378-81. PubMed ID: 3261288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cancer of the kidney in adults. Treatment of the metastatic stage].
    Prog Urol; 1997 Nov; 7(5):879-95. PubMed ID: 9458484
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of malignant melanoma with interleukin-2.
    Philip PA; Flaherty L
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S32-8. PubMed ID: 9122732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is interleukin 2 useful in oncology?].
    Négrier S
    Rev Prat; 1998 Feb; 48(3):237-9. PubMed ID: 9781067
    [No Abstract]   [Full Text] [Related]  

  • 31. [Medical therapy of malignant melanoma].
    Mini E; Periti P
    Ann Ital Chir; 1989; 60(4):257-63. PubMed ID: 2699710
    [No Abstract]   [Full Text] [Related]  

  • 32. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased lysis of melanoma by in vivo-elicited human lymphokine-activated killer cells after addition of antiganglioside antibodies in vitro.
    Harel W; Shau H; Hadley CG; Morgan AC; Reisfeld RA; Cheresh DA; Mitchell MS
    Cancer Res; 1990 Oct; 50(19):6311-5. PubMed ID: 2400994
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 for the treatment of melanoma.
    Tarhini AA; Agarwala SS
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical applications of IL-2.
    Sznol M; Parkinson DR
    Oncology (Williston Park); 1994 Jun; 8(6):61-7; discussion 67, 71, 74-5. PubMed ID: 7521197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC).
    Oldham RK; Lewko WM; Good RW; Sharp E
    In Vivo; 1994; 8(5):653-63. PubMed ID: 7537108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant interleukin-2: a biological response modifier.
    Kintzel PE; Calis KA
    Clin Pharm; 1991 Feb; 10(2):110-28. PubMed ID: 2009728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of high-dose interleukin-2 in a 2-year-old with metastatic melanoma.
    Bernhardt MB; Hicks MJ; Pappo AS
    Pediatr Blood Cancer; 2009 Dec; 53(7):1346-8. PubMed ID: 19731326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.